白三烯抑制剂在慢性炎症性疾病管理中的作用
The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory Diseases.
作者信息
Meshram Deepak, Bhardwaj Khushbo, Rathod Charulata, Mahady Gail B, Soni Kapil K
机构信息
Pharmacogenomics Lab., Department of Biosciences, Barkatullah University, Bhopal (MP) 462026, India.
Department of Zoology, Government P.G. College, BHEL, Bhopal (MP) 462022, India.
出版信息
Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):15-31. doi: 10.2174/1872213X14666200130095040.
BACKGROUND
Leukotrienes are powerful mediators of inflammation and interact with specific receptors in target cell membrane to initiate an inflammatory response. Thus, Leukotrienes (LTs) are considered to be potent mediators of inflammatory diseases including allergic rhinitis, inflammatory bowel disease and asthma. Leukotriene B4 and the series of cysteinyl leukotrienes (C4, D4, and E4) are metabolites of arachidonic acid metabolism that cause inflammation. The cysteinyl LTs are known to increase vascular permeability, bronco-constriction and mucus secretion.
OBJECTIVES
To review the published data for leukotriene inhibitors of plant origin and the recent patents for leukotriene inhibitors, as well as their role in the management of inflammatory diseases.
METHODS
Published data for leukotrienes antagonists of plant origin were searched from 1938 to 2019, without language restrictions using relevant keywords in both free text and Medical Subject Headings (MeSH terms) format. Literature and patent searches in the field of leukotriene inhibitors were carried out by using numerous scientific databases including Science Direct, PubMed, MEDLINE, Google Patents, US Patents, US Patent Applications, Abstract of Japan, German Patents, European Patents, WIPO and NAPRALERT. Finally, data from these information resources were analyzed and reported in the present study.
RESULTS
Currently, numerous anti-histaminic medicines are available including chloropheneremine, brompheniramine, cetirizine, and clementine. Furthermore, specific leukotriene antagonists from allopathic medicines are also available including zileuton, montelukast, pranlukast and zafirlukast and are considered effective and safe medicines as compared to the first generation medicines. The present study reports leukotrienes antagonistic agents of natural products and certain recent patents that could be an alternative medicine in the management of inflammation in respiratory diseases.
CONCLUSION
The present study highlights recent updates on the pharmacology and patents on leukotriene antagonists in the management of inflammation respiratory diseases.
背景
白三烯是强大的炎症介质，可与靶细胞膜上的特定受体相互作用以引发炎症反应。因此，白三烯（LTs）被认为是包括过敏性鼻炎、炎症性肠病和哮喘在内的炎症性疾病的强效介质。白三烯B4和一系列半胱氨酰白三烯（C4、D4和E4）是引起炎症的花生四烯酸代谢产物。已知半胱氨酰白三烯会增加血管通透性、支气管收缩和黏液分泌。
目的
综述已发表的植物源白三烯抑制剂数据、白三烯抑制剂的近期专利及其在炎症性疾病管理中的作用。
方法
使用自由文本和医学主题词（MeSH词）格式的相关关键词，检索1938年至2019年植物源白三烯拮抗剂的已发表数据，无语言限制。通过使用包括Science Direct、PubMed、MEDLINE、谷歌专利、美国专利、美国专利申请、日本摘要、德国专利、欧洲专利、世界知识产权组织和天然产物活性成分数据库（NAPRALERT）在内的众多科学数据库，对白三烯抑制剂领域进行文献和专利检索。最后，对这些信息资源的数据进行分析并在本研究中报告。
结果
目前，有多种抗组胺药物，包括氯苯那敏、溴苯那敏、西替利嗪和氯雷他定。此外，也有来自对抗疗法药物的特定白三烯拮抗剂，包括齐留通、孟鲁司特、普仑司特和扎鲁司特，与第一代药物相比，它们被认为是有效且安全的药物。本研究报告了天然产物的白三烯拮抗剂和某些近期专利，它们可能是治疗呼吸道疾病炎症的替代药物。
结论
本研究突出了白三烯拮抗剂在炎症性呼吸道疾病管理中的药理学和专利方面的最新进展。
Zotero 插件